Surgery for atypical plexiform neurofibromas of the trunk in NF1 with high Standardised Uptake Value (SUV) in Positron-Emission Tomography (PET) expressing podoplanin: A long-term follow-up

Anticancer Research

Volumn 32, Issue 10, 2012, Pages 4547-4551

  Friedrich, Reinhard E ^a   Gawad, Karim ^a   Derlin, Thorsten ^a   Zustin, Jozef ^a   Hagel, Christian ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Atypical neurofibroma; Malignant peripheral nerve sheath tumour; Neurofibromatosis type 1; PET; Podoplanin; Positron emission tomography; Standardised uptake value; SUV

Indexed keywords

FLUORODEOXYGLUCOSE F 18; PODOPLANIN;

ADULT; ARTICLE; CASE REPORT; CELL POPULATION; CELL TRANSFORMATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; NEUROFIBROMATOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHWANN CELL; THORACOTOMY; TREATMENT OUTCOME; TUMOR CELL; TUMOR GROWTH; WHOLE BODY MRI; WHOLE BODY PET;

DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; KI-67 ANTIGEN; MEMBRANE GLYCOPROTEINS; MUCIN-1; NERVE SHEATH NEOPLASMS; NEUROFIBROMA, PLEXIFORM; NEUROFIBROMATOSIS 1; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; S100 PROTEINS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84867772858     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Friedman JM and Riccardi VM: Clinical and epidemiological features. In: Neurofibromatosis. Phenotype, Natural History, and Pathogenesis. JM Friedman, DH Gutmann, M MacCollin and VM Riccardi (eds), The Johns Hopkins University Press, Baltimore and London, pp. 29-86, 1999.
2. Lammert M, Friedman JM, Kluwe L and Mautner VF: Prevalence of neurofibromatosis 1 in German children at elementary school enrollment. Arch Dermatol 141: 71-74, 2005. (Pubitemid 40144442)
3. Scheithauer BW, Woodruff JM and Erlandson RA: Tumors of the Peripheral Nervous System. 3rd Series, Fascicle 24, Armed Forces Institute of Pathology, Washington, pp. 183-218, 1997.
4. Naber U, Friedrich RE, Glatzel M, Mautner VF and Hagel C: Podoplanin and CD34 in peripheral nerve sheath tumours: focus on neurofibromatosis 1-associated atypical neurofibroma. J Neurooncol 103: 239-245, 2011.
5. Ferner RE, Lucas JD, O'Doherty MJ, Hughes RAC, Smith MA, Cronin BF and Bingham J: Evaluation of 18fluorodeoxyglucose positron emission tomography (18FDG-PET) in the detection of malignant peripheral nerve sheath tumors arising from within plexiform neurofibromas in neurofibromatosis 1. J Neurol Neurosurg Psychiatry 68: 353-357, 2000. (Pubitemid 30248712)
6. Ferner RE, Golding JF, Smith M, Calonje E, Jan W, Sanjayanathan V and O'Doherty M: (18 F) 2-fluoro-deoxy-D-glucose positron-emission tomography (FDG-PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumors (MPNSTs): a long-term clinical study. Ann Oncol 19: 390-394, 2008. (Pubitemid 351201726)
7. Mautner VF, Brenner W, Fünsterer C, Hagel C, Gawad K and Friedrich RE: Clinical relevance of positron-emission tomography and magnetic resonance imaging in the progression of internal plexiform neurofibroma in NF1. Anticancer Res 27: 1819-1822, 2007. (Pubitemid 46954681)
8. Benz MR, Czemin J, Dry SM, Tap WD, Allen-Auerbach MS, Elashoff D, Phelps ME, Weber WA and Eilber PC: Quantitative F18-fluorodeoxyglucose positron-emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign. Cancer 116: 451-458, (erratum: 116:775), 2010.
9. Brenner W, Friedrich RE, Gawad K, Hagel C, von Deimling A, de Wit M, Buchert R, Clausen M and Mautner VF: Prognostic relevance of FDG-PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumor. Eur J Nucl Med Mol Imaging 33: 428-432, 2006.
10. Bredella MA, Torriani M, Hornicek F, Ouellette HA, Palmer WE, Williams Z, Fischman AJ and Plotkin S: Value of PET in the assessment of patients with neurofibromatosis type 1. Am J Roentgenol 189: 928-935, 2007. (Pubitemid 47479778)
11. Karabatsou K, Kiehl TR, Wilson DM, Hendler A and Guha A: Potential role of 18fluorodeoxyglucose positron-emission tomography/computed tomography in differentiating benign neurofibroma from malignant peripheral nerve sheath tumor associated with neurofibromatosis 1. Neurosurg 65 (Suppl 4): 160-170, 2009.
12. Friedrich RE, Derlin T and Hagel C: Atypical plexiform neurofibroma in NF1 with high standardised uptake value (SUV) in positron-emission tomography (PET) expressing podoplanin. In Vivo 24: 871-876, 2010.
13. Yu H, Gibson JA, Pinkus GS and Hornick JL: Podoplanin (D2-40) is a novel marker for follicular dendritic cell tumors. Am J Clin Pathol 128: 776-782, 2007. (Pubitemid 350133988)
14. Jokinen CH, Dadras SS, Goldblum JR, van de Rijn M, West RB and Rubin BP: Diagnostic implications of podoplanin expression in peripheral nerve sheath neoplasms. Am J Clin Pathol 129: 886-893, 2008.
15. Gutmann DH, Aylsworth A, Carey JC, Korf B, Marks J, Pyeritz RE, Rubenstein A and Viskochil D: The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 278: 51-57, 1997. (Pubitemid 27274517)
16. Warbey VS, Ferner RE, Dunn JT, Calonje E and O'Doherty MJ: FDG-PET/CT in the diagnosis of malignant peripheral nerve sheath tumors in neurofibromatosis type-1. Eur J Nucl Med Mol Imaging 36: 751-757, 2009.
17. Mautner VF, Friedrich RE, von Deimling A, Hagel C, Korf B, Knöfel MT, Wenzel R and Fünsterer C: Malignant peripheral nerve sheath tumors in neurofibromatosis type 1: MRI supports the diagnosis of malignant plexiform neurofibroma. Neuroradiol 45: 618-624, 2003.
18. Valeyrie-Allanore L, Ismaïli N, Bastuji-Garin S, Zeller J, Wechsler J, Revuz J and Wolkenstein P: Symptoms associated with malignancy of peripheral nerve sheath tumors: A retrospective study of 69 patients with neurofibromatosis 1. Br J Dermatol 153: 79-82, 2005. (Pubitemid 41044531)
19. Valeyrie-Allanore L, Ortonne N, Lantieri L, Ferkal S, Wechsler J, Bagot M and Wolkenstein P: Histopathologically dysplastic neurofibromas in neurofibromatosis 1: diagnostic criteria, prevalence and clinical significance. Br J Dermatol 158: 1008-1012, 2008. (Pubitemid 351521455)
20. Kahn HJ and Marks A: A novel monoclonal antibody, D2-40, for detection of lymphatic invasion in primary tumors. Lab Invest 82: 1255-1257, 2002 (Pubitemid 35014860)
21. Fukunaga M: Expression of D2-40 in lymphatic endothelium of normal tissues and in vascular tumours. Histopathol 46: 396-402, 2005.
22. Schacht V, Dadras SS, Johnson LA, Jackson DG, Hong YK and Detmar M: Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. Am J Pathol 166: 913-921, 2005. (Pubitemid 40315647)
23. Gomaa AHA, Yaar M and Bhawan J: Cutaneous immunoreactivity of D2-40 antibody beyond the lymphatics. Am J Dermatopathol 29: 18-21, 2007. (Pubitemid 46220234)
24. Sonne SB, Herlihy AS, Hoei-Hansen CE, Nielsen JE, Almstrup K, Skakkebaek NE, Marks A, Leffers H and Rajpert-De Meyts E: Identity of M2A (D2-40) antigen and GP36 (aggrus, T1A-2, podoplanin) in human developing testis, testicular carcinoma in situ and germ-cell tumors. Virchows Arch 449: 200-206, 2006.
25. Zustin J, Scheuer HA and Friedrich RE: Podoplanin expression in human tooth germ tissues and cystic odontogenic lesions: an immunohistochemical study. J Oral Pathol Med 39: 115-120, 2010.
26. Nakamura Y, Kanemura Y, Yamada T, Sugita Y, Higaki K, Yamamoto M, Takahashi M and Yamasaki M: D2-40 antibody immunoreactivity in developing human brain, brain tumors and cultured neural cells. Mod Pathol 19: 974-985, 2006.
27. Jokinen CH, Dadras SS, Goldblum JR, van de Rijn M, West RB and Rubin BP: Diagnostic implications of podoplanin expression in peripheral nerve sheath neoplasms. Am J Clin Pathol 129: 886-893, 2008.